Novel drug targets based on metallobiology of Alzheimer's disease

Sanghamitra Bandyopadhyay, Xudong Huang, Debomoy Lahiri, Jack T. Rogers

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Importance of the field: Increased localization of Zn, Fe, Cu and Al within the senile plaques (SP) exacerbates amyloid beta (Aβ)-mediated oxidative damage, and acts as catalyst for Aβ aggregation in Alzheimer's disease (AD). Thus, disruption of aberrant metalpeptide interactions via chelation therapy holds considerable promise as a rational therapeutic strategy against Alzheimer's amyloid pathogenesis. Areas covered in this review: The complexities of metal-induced genesis of SP are reviewed. The recent advances in the molecular mechanism of action of metal chelating agents are discussed with critical assessment of their potential to become drugs. What the reader will gain: Taking into consideration the interaction of metals with the metal-responsive elements on the Alzheimer's amyloid precursor protein (APP), readers will gain understanding of several points to bear in mind when developing a screening campaign for AD-therapeutics. Take home message: A functional iron-responsive element (IRE) RNA stem loop in the 5′ untranslated region (UTR) of the APP transcript regulates neural APP translation. Desferrioxamine, clioquinol, tetrathiolmolybdate, dimercaptopropanol, VK-28, and natural antioxidants, such as curcumin and ginko biloba need critical evaluation as AD therapeutics. There is a necessity for novel screens (related to metallobiology) to identify therapeutics effective in AD.

Original languageEnglish
Pages (from-to)1177-1197
Number of pages21
JournalExpert Opinion on Therapeutic Targets
Volume14
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

Amyloid beta-Protein Precursor
Alzheimer Disease
Amyloid
Metals
Amyloid Plaques
Pharmaceutical Preparations
Clioquinol
Chelation Therapy
Ginkgo biloba
Curcumin
Deferoxamine
5' Untranslated Regions
Protein Biosynthesis
Therapeutics
Chelating Agents
Chelation
Screening
Agglomeration
Iron
Antioxidants

Keywords

  • APP
  • Iron responsive element
  • Metal chelators
  • Screening

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Novel drug targets based on metallobiology of Alzheimer's disease. / Bandyopadhyay, Sanghamitra; Huang, Xudong; Lahiri, Debomoy; Rogers, Jack T.

In: Expert Opinion on Therapeutic Targets, Vol. 14, No. 11, 11.2010, p. 1177-1197.

Research output: Contribution to journalArticle

Bandyopadhyay, Sanghamitra ; Huang, Xudong ; Lahiri, Debomoy ; Rogers, Jack T. / Novel drug targets based on metallobiology of Alzheimer's disease. In: Expert Opinion on Therapeutic Targets. 2010 ; Vol. 14, No. 11. pp. 1177-1197.
@article{9ad4a01604e24915890ae2af565c8b80,
title = "Novel drug targets based on metallobiology of Alzheimer's disease",
abstract = "Importance of the field: Increased localization of Zn, Fe, Cu and Al within the senile plaques (SP) exacerbates amyloid beta (Aβ)-mediated oxidative damage, and acts as catalyst for Aβ aggregation in Alzheimer's disease (AD). Thus, disruption of aberrant metalpeptide interactions via chelation therapy holds considerable promise as a rational therapeutic strategy against Alzheimer's amyloid pathogenesis. Areas covered in this review: The complexities of metal-induced genesis of SP are reviewed. The recent advances in the molecular mechanism of action of metal chelating agents are discussed with critical assessment of their potential to become drugs. What the reader will gain: Taking into consideration the interaction of metals with the metal-responsive elements on the Alzheimer's amyloid precursor protein (APP), readers will gain understanding of several points to bear in mind when developing a screening campaign for AD-therapeutics. Take home message: A functional iron-responsive element (IRE) RNA stem loop in the 5′ untranslated region (UTR) of the APP transcript regulates neural APP translation. Desferrioxamine, clioquinol, tetrathiolmolybdate, dimercaptopropanol, VK-28, and natural antioxidants, such as curcumin and ginko biloba need critical evaluation as AD therapeutics. There is a necessity for novel screens (related to metallobiology) to identify therapeutics effective in AD.",
keywords = "Aβ, APP, Iron responsive element, Metal chelators, Screening",
author = "Sanghamitra Bandyopadhyay and Xudong Huang and Debomoy Lahiri and Rogers, {Jack T.}",
year = "2010",
month = "11",
doi = "10.1517/14728222.2010.525352",
language = "English",
volume = "14",
pages = "1177--1197",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Novel drug targets based on metallobiology of Alzheimer's disease

AU - Bandyopadhyay, Sanghamitra

AU - Huang, Xudong

AU - Lahiri, Debomoy

AU - Rogers, Jack T.

PY - 2010/11

Y1 - 2010/11

N2 - Importance of the field: Increased localization of Zn, Fe, Cu and Al within the senile plaques (SP) exacerbates amyloid beta (Aβ)-mediated oxidative damage, and acts as catalyst for Aβ aggregation in Alzheimer's disease (AD). Thus, disruption of aberrant metalpeptide interactions via chelation therapy holds considerable promise as a rational therapeutic strategy against Alzheimer's amyloid pathogenesis. Areas covered in this review: The complexities of metal-induced genesis of SP are reviewed. The recent advances in the molecular mechanism of action of metal chelating agents are discussed with critical assessment of their potential to become drugs. What the reader will gain: Taking into consideration the interaction of metals with the metal-responsive elements on the Alzheimer's amyloid precursor protein (APP), readers will gain understanding of several points to bear in mind when developing a screening campaign for AD-therapeutics. Take home message: A functional iron-responsive element (IRE) RNA stem loop in the 5′ untranslated region (UTR) of the APP transcript regulates neural APP translation. Desferrioxamine, clioquinol, tetrathiolmolybdate, dimercaptopropanol, VK-28, and natural antioxidants, such as curcumin and ginko biloba need critical evaluation as AD therapeutics. There is a necessity for novel screens (related to metallobiology) to identify therapeutics effective in AD.

AB - Importance of the field: Increased localization of Zn, Fe, Cu and Al within the senile plaques (SP) exacerbates amyloid beta (Aβ)-mediated oxidative damage, and acts as catalyst for Aβ aggregation in Alzheimer's disease (AD). Thus, disruption of aberrant metalpeptide interactions via chelation therapy holds considerable promise as a rational therapeutic strategy against Alzheimer's amyloid pathogenesis. Areas covered in this review: The complexities of metal-induced genesis of SP are reviewed. The recent advances in the molecular mechanism of action of metal chelating agents are discussed with critical assessment of their potential to become drugs. What the reader will gain: Taking into consideration the interaction of metals with the metal-responsive elements on the Alzheimer's amyloid precursor protein (APP), readers will gain understanding of several points to bear in mind when developing a screening campaign for AD-therapeutics. Take home message: A functional iron-responsive element (IRE) RNA stem loop in the 5′ untranslated region (UTR) of the APP transcript regulates neural APP translation. Desferrioxamine, clioquinol, tetrathiolmolybdate, dimercaptopropanol, VK-28, and natural antioxidants, such as curcumin and ginko biloba need critical evaluation as AD therapeutics. There is a necessity for novel screens (related to metallobiology) to identify therapeutics effective in AD.

KW - Aβ

KW - APP

KW - Iron responsive element

KW - Metal chelators

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=77958046282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958046282&partnerID=8YFLogxK

U2 - 10.1517/14728222.2010.525352

DO - 10.1517/14728222.2010.525352

M3 - Article

VL - 14

SP - 1177

EP - 1197

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 11

ER -